CA2936963A1 - Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof - Google Patents

Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof Download PDF

Info

Publication number
CA2936963A1
CA2936963A1 CA2936963A CA2936963A CA2936963A1 CA 2936963 A1 CA2936963 A1 CA 2936963A1 CA 2936963 A CA2936963 A CA 2936963A CA 2936963 A CA2936963 A CA 2936963A CA 2936963 A1 CA2936963 A1 CA 2936963A1
Authority
CA
Canada
Prior art keywords
liposome
cyclodextrin
liposome composition
therapeutic agent
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2936963A
Other languages
English (en)
French (fr)
Inventor
Bert Vogelstein
Kenneth W. Kinzler
Shibin Zhou
Surojit Sur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA2936963A1 publication Critical patent/CA2936963A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2936963A 2014-01-14 2015-01-14 Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof Abandoned CA2936963A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927233P 2014-01-14 2014-01-14
US61/927,233 2014-01-14
PCT/US2015/011342 WO2015108932A1 (en) 2014-01-14 2015-01-14 Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof

Publications (1)

Publication Number Publication Date
CA2936963A1 true CA2936963A1 (en) 2015-07-23

Family

ID=53543384

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2936963A Abandoned CA2936963A1 (en) 2014-01-14 2015-01-14 Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof

Country Status (8)

Country Link
US (2) US20180161274A1 (enExample)
EP (1) EP3094313A4 (enExample)
JP (1) JP2017502985A (enExample)
CN (1) CN106659683A (enExample)
AU (1) AU2015206628A1 (enExample)
CA (1) CA2936963A1 (enExample)
HK (1) HK1231397A1 (enExample)
WO (1) WO2015108932A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3370712B1 (en) 2015-11-06 2025-02-19 The Johns Hopkins University 3-bromopyruvate for treating liver fibrosis
SG10202107836SA (en) * 2017-01-18 2021-08-30 Temasek Life Sciences Laboratory Ltd Hyperstabilized liposomes increase targeting of mitotic cells
CN108478533B (zh) * 2018-04-23 2020-12-08 滨州医学院 β环糊精-LPC脂质体制备方法及其作为药物载体的应用
CN112384226B (zh) * 2018-07-06 2024-06-28 丸大食品株式会社 含有缩醛磷脂的组合物
CN108853111B (zh) * 2018-08-07 2020-06-05 浙江大学 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用
CN111449187B (zh) * 2020-05-09 2022-10-14 扬州大学 一种布氏乳杆菌S-层蛋白修饰的香芹酚/β-环糊精脂质体及其制备方法和抗菌用途
EP4026945A1 (en) * 2021-01-07 2022-07-13 Calik Denim Tekstil San. Ve Tic. A.S. Encapsulated indigo
CN114113426B (zh) * 2021-12-27 2024-04-26 西安血氧生物技术有限公司 一种血红蛋白氧载体中磷脂的检测方法
CN115386262B (zh) * 2022-09-26 2023-05-12 杭州海维特化工科技有限公司 一种应用于汽车内饰装饰塑料膜的缓释香精和负离子的凹印水墨及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04500229A (ja) * 1988-08-31 1992-01-16 オーストレイリアン・コマーシヤル・リサーチ・アンド・デイベロツプメント・リミテツド 薬剤分配用及びクロマトグラフィー用の組成物及び方法
ES2036504A6 (es) * 1990-03-02 1993-05-16 Australian Commercial Research Procedimiento para preparar complejos de ciclodextrina.
AU6818094A (en) * 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
DE19814815C2 (de) * 1998-04-02 2000-10-12 Gerhard Steffan Sterinverknüpfte, anionische Cyclodextrinderivate und deren Verwendung in Arzneimittelformulierungen
CN1813679A (zh) * 2005-11-30 2006-08-09 上海医药(集团)有限公司 一种紫杉烷脂质体冻干组合物及其制备方法
CN101653414B (zh) * 2008-08-19 2011-07-20 中国科学院上海药物研究所 多西他赛长循环固体脂质纳米粒及其制备方法
EP2415464B1 (en) * 2009-03-30 2017-05-10 Eisai R&D Management Co., Ltd. Method for producing liposome composition
CN102596178B (zh) * 2009-10-26 2014-12-03 石药集团中奇制药技术（石家庄）有限公司 具有磺丁基醚环糊精盐内水相的脂质体
CN102397248A (zh) * 2010-09-15 2012-04-04 万物(北京)医药科技发展有限公司 一种辛二酰苯胺异羟肟酸环糊精包合物脂质体
ES2770575T3 (es) * 2010-10-28 2020-07-02 Pacira Pharmaceuticals Inc Formulación de liberación sostenida de un fármaco antiinflamatorio no esteroideo
WO2012118376A1 (en) * 2011-03-01 2012-09-07 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances
WO2014004651A1 (en) * 2012-06-26 2014-01-03 The Johns Hopkins University Multifunctional tunable biomaterials for tissue engineering
WO2014121235A2 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes

Also Published As

Publication number Publication date
HK1231397A1 (zh) 2017-12-22
AU2015206628A1 (en) 2016-08-25
US20180161274A1 (en) 2018-06-14
WO2015108932A1 (en) 2015-07-23
EP3094313A4 (en) 2017-07-12
EP3094313A1 (en) 2016-11-23
CN106659683A (zh) 2017-05-10
JP2017502985A (ja) 2017-01-26
US20190328665A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
US20190328665A1 (en) Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof
Chen et al. Nanobowl-supported liposomes improve drug loading and delivery
Ahmed et al. Liposome: composition, characterisation, preparation, and recent innovation in clinical applications
Çağdaş et al. Liposomes as Potential Drug Carrier Systems for Drug
Jadhav et al. Novel vesicular system: an overview
EP3787607B1 (en) Carotenoid compositions and uses thereof
JP5770336B2 (ja) リポソーム組成物の製造方法
JP5551683B2 (ja) リポソーム組成物
JP2022003102A (ja) 異なる医薬品の制御送達のためのビヒクル
DE60122304T2 (de) Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe
Liu et al. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent
Qian et al. Pharmacokinetics and disposition of various drug loaded liposomes
EP2384743A1 (en) Siosomal formulation for intracellular delivery and targeting of therapeutic agents
CN117897140A (zh) 用于制备脂质体制剂的方法
Sirisha et al. Liposomes-the potential drug carriers
JP2020521004A (ja) ｃ（ＲＧＤ−ＡＣＰ−Ｋ）修飾血中滞留型リポソーム
US20220378936A1 (en) Delivery system complexes comprising a precipitate of an active agent and methods of use
US10925831B2 (en) Liposomal formulations of platinum-acridine anticancer agents and methods thereof
JP5817053B2 (ja) 腫瘍特異性を有するリポソーム
WO2022124898A1 (en) Auristatin-loaded liposomes and uses thereof.
Batra et al. Liposomal Drug Delivery
Khan et al. Composition and Application of Liposome as a Carrier for Cancer Therapy
WO2025184543A1 (en) Compositions and methods for delivery of therapeutic compounds
AU2014200717A1 (en) Liposome composition
BR102017018582B1 (pt) Lipossomas, processo de obtenção, composições antitumorais e usos

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831

FZDE Discontinued

Effective date: 20210831

FZDE Discontinued

Effective date: 20210831